3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
18
Gastrointestinal
8
CNS
5
Plasma cell
2
Lymphoid
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Neoplasms
1
Interventions
Rituximab
689
Cyclophosphamide
615
Vincristine
285
Etoposide
272
Doxorubicin
271
Cytarabine
230
Prednisone
229
Methotrexate
221
fludarabine phosphate
189
Filgrastim
187
Dexamethasone
180
fludarabine
176
Lenalidomide
165
Radiotherapy
128
Melphalan
127
Peripheral Blood Stem Cell Transplantation
123
Busulfan
118
Bendamustine Hydrochloride
116
Granulocyte Colony-Stimulating Factor
113
Bortezomib
112
ibrutinib
111
Mycophenolic Acid
110
venetoclax
106
Whole-Body Irradiation
106
obinutuzumab
105
Tacrolimus
105
Gemcitabine
92
zanubrutinib
81
Specimen Handling
80
Cyclosporine
76
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
tucatinib
×
Lymphoid
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled